Pharmaceutical Commerce - February 2022 Issue (PDF)

Mitigating Drug Shortages

Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.

April 12th 2024

LogiPharma Europe 2024: Properly Applying Diversity, Equity, and Inclusion Initiatives Within the Life Sciences Supply Chain

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

A Further Examination of Pharmacy Benefit Managers

Panel discussion addresses how DE&I can successfully tackle systemic biases and more.

March 29th 2024

LogiPharma Europe 2024: Obstacles Surrounding Personalized Therapy Supply Chains

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

April 18th 2024

Pharma Pulse 4/18/24: Certain Biotech Investors Get an Early Look at Results, An Ethical Outlook for Obesity Drugs & more

Session addresses the challenges of implementing autologous/allogeneic cell gene therapies into scalable networks.

April 18th 2024

FDA Approves Takeda’s Subcutaneous Form of Entyvio as a Maintenance Therapy in Adults with Moderately to Severe Crohn Disease

The latest news for pharma industry insiders.

Related Content

Mitigating Drug Shortages

Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.

April 12th 2024

LogiPharma Europe 2024: Properly Applying Diversity, Equity, and Inclusion Initiatives Within the Life Sciences Supply Chain

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

A Further Examination of Pharmacy Benefit Managers

Panel discussion addresses how DE&I can successfully tackle systemic biases and more.

March 29th 2024